Chimerix - CMRX STOCK NEWS

Chimerix (NASDAQ:CMRX) reported its Q1 2021 financial results, revealing a net loss of $97.4 million, significantly higher than the $10.4 million loss from Q1 2020. Revenues increased slightly to $1.4 million from $1.2 million year-over-year. R&D expenses rose to $11.9 million, and total operational losses reached $97.5 million. Upcoming milestones include the PDUFA date for BCV for smallpox set for July 7, and progress in trials for DSTAT and ONC201. The company has $152.5 million in capital available for operations, but significant financial challenges remain.

Chimerix (CMRX) will host a conference call on May 6, 2021, at 8:30 a.m. ET to report its Q1 2021 financial results and provide an operational update. Investors can join by calling (877) 354-4056 domestically or (678) 809-1043 internationally. The company, focused on developing drugs for cancer and serious diseases, is advancing three main clinical programs: BCV for smallpox, ONC201 for H3 K27M-mutant glioma, and DSTAT for acute myeloid leukemia and COVID-19-related lung injury. Risks associated with their drug approvals and trials were also outlined.

Chimerix (NASDAQ:CMRX) has appointed Vicki Vakiener to its Board of Directors, effective immediately. With over 20 years of oncology commercial leadership experience, Vakiener enhances Chimerix's capabilities as the company advances its late-stage programs. She previously led successful commercial efforts at Epizyme and Johnson & Johnson, overseeing oncology products including ZYTIGA and IMBRUVICA. Chimerix focuses on developing innovative treatments for cancer and other serious diseases, with key programs like BCV, ONC201, and DSTAT currently in various stages of clinical development.

Chimerix (NASDAQ:CMRX) announced poster presentations at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, occurring from April 10-15 and May 17-21. Highlights include:

• ONC201's efficacy in brain tumors and combination therapies.
• ONC206's role in ovarian cancer suppression.
• ONC212's impact in pancreatic cancer.

Presentations are scheduled for April 10, 2021, featuring experts from Brown University and Chimerix. Posters will be accessible on the AACR website from the same date.

DURHAM, N.C., March 2, 2021 - Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET. The presentation will be available via an audio webcast on the Investor Relations section of Chimerix's website, archived for 90 days.

Chimerix focuses on developing medicines for cancer and severe diseases, with leading programs including BCV, ONC201, and DSTAT, aiming for regulatory approval for BCV as a smallpox treatment.

Cantex Pharmaceuticals announced that Chimerix, the worldwide licensee of its DSTAT product, reported promising results from the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI). Early data suggests that dociparstat sodium (DSTAT) may accelerate recovery and reduce thrombotic events in these patients. Cantex is actively involved in the development of DSTAT for ALI and other indications, alongside its other product candidate, Dicopp, which targets long-term complications of COVID-19.

Chimerix (CMRX) announced its acquisition of Oncoceutics, enhancing its oncology pipeline with ONC201, a promising agent targeting recurrent H3 K27M-mutant glioma. The company reported a net loss of $11.7 million for Q4 2020, with revenues falling to $1.1 million, down from $6.8 million in Q4 2019. Research and development expenses increased to $8.7 million, while the total capital available rose to approximately $159.8 million post-financing. Chimerix also provided an updated PDUFA date for brincidofovir, extended to July 7, 2021, as it progresses through its clinical trials.

Chimerix (CMRX) announced positive topline results from its Phase 2/3 study of DSTAT for hospitalized patients with Acute Lung Injury (ALI) and COVID-19. In the first cohort of 12 patients, none on DSTAT required mechanical ventilation, while two on placebo progressed to ventilation and died. All six DSTAT patients showed significant clinical improvement according to the NIAID scale, in contrast to two on placebo. Future results from a second, fully enrolled cohort are anticipated in Q2 2021, potentially paving the way for DSTAT as a therapeutic option for severe COVID-19 cases.

Chimerix (NASDAQ:CMRX) announced a live conference call on February 25, 2021, at 8:30 a.m. ET to discuss its fourth-quarter and full-year financial results ending December 31, 2020. The call will include a business overview, with access available via phone or webcast. Chimerix focuses on developing medicines for serious diseases, with ongoing programs for BCV, ONC201, and DSTAT. Notably, BCV is under review for regulatory approval, and ONC201 is in a registrational trial for glioma. The company remains committed to advancing innovative therapies, reflecting its dedication to patients.